PURPOSE: The aims of this study are to establish a time point to determine the most beneficial time to administer GCEE post incident to reduce oxidative damage and second, by using redox proteomics, to determine if GCEE can readily suppress 3-NT modification in TBI animals. EXPERIMENTAL DESIGN: By using a moderate traumatic brain injury model with Wistar rats, it is hypothesized that the role of 3-nitrotyrosine (3-NT) formation as an intermediate will predict the involvement of protein nitration/nitrosation and oxidative damage in the brain. RESULTS: In this experiment, the levels of protein carbonyls, 4-hydroxynonenal, and 3-nitrotyrosine were significantly elevated in TBI injured, saline treated rats compared with those who sustained an injury and were treated with 150 mg/kg of the glutathione mimetic, GCEE. CONCLUSION AND CLINICAL RELEVANCE: Determining the existence of elevated 3-NT levels provides insight into the relationship between the protein nitration/nitrosation and the oxidative damage, which can determine the pathogenesis and progression of specific neurological diseases.
PURPOSE: The aims of this study are to establish a time point to determine the most beneficial time to administer GCEE post incident to reduce oxidative damage and second, by using redox proteomics, to determine if GCEE can readily suppress 3-NT modification in TBI animals. EXPERIMENTAL DESIGN: By using a moderate traumatic brain injury model with Wistar rats, it is hypothesized that the role of 3-nitrotyrosine (3-NT) formation as an intermediate will predict the involvement of protein nitration/nitrosation and oxidative damage in the brain. RESULTS: In this experiment, the levels of protein carbonyls, 4-hydroxynonenal, and 3-nitrotyrosine were significantly elevated in TBI injured, saline treated rats compared with those who sustained an injury and were treated with 150 mg/kg of the glutathione mimetic, GCEE. CONCLUSION AND CLINICAL RELEVANCE: Determining the existence of elevated 3-NT levels provides insight into the relationship between the protein nitration/nitrosation and the oxidative damage, which can determine the pathogenesis and progression of specific neurological diseases.
Authors: Fiona Crawford; Gogce Crynen; Jon Reed; Benoit Mouzon; Alex Bishop; Benjamin Katz; Scott Ferguson; John Phillips; Vani Ganapathi; Venkatarajan Mathura; Allen Roses; Michael Mullan Journal: J Neurotrauma Date: 2011-12-07 Impact factor: 5.269
Authors: Mona Bains; John E Cebak; Lesley K Gilmer; Colleen C Barnes; Stephanie N Thompson; James W Geddes; Edward D Hall Journal: J Neurochem Date: 2013-01-28 Impact factor: 5.372
Authors: Yimin Ren; Hong Wei Xu; Fleur Davey; Margaret Taylor; Jim Aiton; Peter Coote; Fang Fang; Jun Yao; Doris Chen; John Xi Chen; Shi Du Yan; Frank J Gunn-Moore Journal: J Biol Chem Date: 2007-12-31 Impact factor: 5.157
Authors: Benjamin Gaston; Santhosh M Baby; Walter J May; Alex P Young; Alan Grossfield; James N Bates; James M Seckler; Christopher G Wilson; Stephen J Lewis Journal: Sci Rep Date: 2021-05-11 Impact factor: 4.379
Authors: Michael W Jenkins; Faiza Khalid; Santhosh M Baby; Walter J May; Alex P Young; James N Bates; Feixiong Cheng; James M Seckler; Stephen J Lewis Journal: Sci Rep Date: 2021-03-26 Impact factor: 4.379
Authors: Paulina M Getsy; Santhosh M Baby; Walter J May; Alex P Young; Benjamin Gaston; Matthew R Hodges; Hubert V Forster; James N Bates; Christopher G Wilson; Tristan H J Lewis; Yee-Hee Hsieh; Stephen J Lewis Journal: Front Pharmacol Date: 2022-06-23 Impact factor: 5.988
Authors: Paulina M Getsy; Santhosh M Baby; Walter J May; James N Bates; Christopher R Ellis; Michael G Feasel; Christopher G Wilson; Tristan H J Lewis; Benjamin Gaston; Yee-Hsee Hsieh; Stephen J Lewis Journal: Front Pharmacol Date: 2022-09-28 Impact factor: 5.988
Authors: James R Mester; Paolo Bazzigaluppi; Adrienne Dorr; Tina Beckett; Matthew Burke; JoAnne McLaurin; John G Sled; Bojana Stefanovic Journal: Theranostics Date: 2021-06-16 Impact factor: 11.556